3 assets in Malignant Leptomeningeal Tumor

Therapeutic assets addressing Malignant Leptomeningeal Tumor, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Nivolumab Malignant Leptomeningeal Tumor	M.D. Anderson Cancer Center	P1	CC (43)
Sapanisertib Malignant Leptomeningeal Tumor	National Cancer Institute (NCI)	P1	CC (43)
Telaglenastat Malignant Leptomeningeal Tumor	National Cancer Institute (NCI)	P1	CC (43)